Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of QCC374 in PAH
NCT02939599Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of QCC374 in pulmonary arterial hypertension (PAH), sponsored by Novartis. Primary endpoint: Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs) at 2 years. Started Feb 2018; status: terminated.
02
Drugs
QCC374
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02939599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939599.